Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 USD | +3.85% | -3.57% | -15.09% |
May. 24 | Cyclo Therapeutics Files $100 Million Mixed Shelf | MT |
May. 01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
Financials (USD)
Sales 2024 * | 1.2M | Sales 2025 * | 2.11M | Capitalization | 38.77M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -23M | EV / Sales 2024 * | 32.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 18.4 x |
P/E ratio 2024 * |
-1.82
x | P/E ratio 2025 * |
-2.25
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.38% |
1 day | +3.85% | ||
1 week | -3.57% | ||
Current month | -7.53% | ||
1 month | +4.65% | ||
3 months | -22.86% | ||
6 months | +4.65% | ||
Current year | -15.09% |
Managers | Title | Age | Since |
---|---|---|---|
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Joshua Fine
DFI | Director of Finance/CFO | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
William Shanahan
BRD | Director/Board Member | 84 | 16-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 1.35 | +3.85% | 28,979 |
24-05-23 | 1.3 | +0.78% | 53,703 |
24-05-22 | 1.29 | -5.15% | 23,999 |
24-05-21 | 1.36 | -4.23% | 24,642 |
24-05-20 | 1.42 | +1.43% | 15,001 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.09% | 38.77M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- CYTH Stock